Boehringer Ingelheim leads early-stage round for Amal

The fresh capital will enable the spinout from the University of Geneva to consolidate its cell-penetrating, peptide-based technology platform and to progress the first vaccine candidate up to pre-clinical development.

Company
Founded in September 2012, Amal is headquartered in Geneva with an office in Berlin. The company employs less than 10 staff members and has not yet commercialised its product.

Amal is developing a recombinant protein-based vaccine and is looking to use its proprietary cell-penetrating peptide platform to develop and progress therapeutic vaccines in the field of oncology.

People
Madiha Derouazi is the founder and CEO of Amal Therapeutics. BIVF director and investment manager Knut Elbers joined the company's board of directors following the funding round.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Early-stage
• High-Tech Gründerfonds
• Switzerland